Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Women's Hospital
Novartis
Information provided by (Responsible Party):
Richard Stone, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00819546
First received: January 8, 2009
Last updated: February 19, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)